Fisher Asset Management LLC Lowers Stock Position in Bristol Myers Squibb Company $BMY

Fisher Asset Management LLC cut its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 5.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 204,728 shares of the biopharmaceutical company’s stock after selling 11,414 shares during the period. Fisher Asset Management LLC’s holdings in Bristol Myers Squibb were worth $11,043,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Darwin Wealth Management LLC purchased a new position in Bristol Myers Squibb during the second quarter valued at $25,000. Physician Wealth Advisors Inc. lifted its holdings in Bristol Myers Squibb by 73.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 202 shares in the last quarter. EQ Wealth Advisors LLC purchased a new position in Bristol Myers Squibb during the fourth quarter valued at $32,000. KERR FINANCIAL PLANNING Corp purchased a new position in Bristol Myers Squibb during the third quarter valued at $35,000. Finally, Garner Asset Management Corp purchased a new position in Bristol Myers Squibb during the fourth quarter valued at $35,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb Stock Performance

NYSE:BMY opened at $57.63 on Thursday. The company’s 50-day moving average price is $58.42 and its 200-day moving average price is $56.18. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. The company has a market cap of $117.68 billion, a P/E ratio of 16.19, a P/E/G ratio of 0.17 and a beta of 0.26. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $1.42 by $0.16. The firm had revenue of $11.49 billion for the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period last year, the firm posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, sell-side analysts forecast that Bristol Myers Squibb Company will post 6.31 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd were paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 4.4%. The ex-dividend date of this dividend was Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 70.79%.

Insider Buying and Selling at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 30,000 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the transaction, the executive vice president directly owned 159,248 shares of the company’s stock, valued at approximately $9,820,824.16. This trade represents a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 0.05% of the company’s stock.

Analyst Upgrades and Downgrades

BMY has been the topic of several recent analyst reports. Royal Bank Of Canada initiated coverage on shares of Bristol Myers Squibb in a report on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 price objective on the stock. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Sunday, April 19th. Barclays began coverage on shares of Bristol Myers Squibb in a report on Thursday, February 19th. They set an “overweight” rating and a $75.00 price objective on the stock. UBS Group reiterated a “buy” rating and set a $70.00 price target on shares of Bristol Myers Squibb in a research report on Friday, March 6th. Finally, Bank of America dropped their price target on Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating for the company in a research report on Thursday, April 9th. Eight equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $61.31.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.